Can we predict PsA incidence and prevalence trends? Germany long-term projection 2040 3 scenarios: 1. increase 5%/yr 2. stable 3. decrease 5%/yr. Best scenario (3) = peak diagnoses in 2028. Are medical resources ready for it? https://t.co/ws87zDukuM Abs#1019 #ACR22 @Rheumnow https://t.co/dqkfrag0w2

• Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Proje…

Atypical femoral fracture risk increases over time. Risk decreases slowly as well with time off treatment. Absolute risk remains relatively low however. @RheumNow #ACR22 #osteoporosis https://t.co/pcIfhRW4WJ

💉COVID-19 vaccination in pregnant pts with rheumatic disease💉 🤰⬇️pre term births in vaccinated 🤰PPROM ⬆️ unvaccinated ✅More support 4 importance of covid vacc in our 🤰 Stellar work from covid GRA- Fantastic presentation by @Sineadm15 #ACR22 @RheumNow @RichardPAConway https://t.co/LLaLJSqS6W

Good BMD gains in switching BP->denosumab, especially in first few years. #sequentialtherapy @RheumNow #ACR22 #osteoporosis https://t.co/t1hItKn8sB

Most rheums round down on dosing because of the weight based recc's, but hydroxychloroquine dosing less than 5 Mg/kg/day leads to increased hospitalizations for #SLE flares abst#1654 #ACR22 #PressConference @rheumnow https://t.co/GGnnl14cy9

• Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizat…

Phase 1 data shows Ebdarokimab (IL12/23i) safe and well tolerated in moderate to severe plaque psoriasis patients. Abs 0752 #ACR22 @RheumNow https://t.co/QqTE4WJtDa https://t.co/eMaEurZAr0

• A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics an…

The great debate Next steps to develop RA prevention Kevin Deane “It’s time to move from disease modifying drugs to disease modifying therapeutic approaches” #ACRdebate #ACR22 @RheumNow https://t.co/3vt58sXlDx

Advancing Telemedicine in Rheumatology 'We all became Zoomatologists (Zheum-atologists?) since COVID.' -Jack Cush @RheumNow @RheumNow #ACR22

Pts w/ pre-existing rheumatic conditions 3.6 times likelier to new rheumatic disease features or worsening disease after starting ICI for melanoma, Abs 0756 #ACR22 @RheumNow https://t.co/s1f1QxmJzA https://t.co/6cKllBzqJn

• Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced …

Osteoporotic fx in AS Abstract #0388 #ACR22 @RheumNow 🦴2k adults in RISE, mean age 68y, 44% female, 76% white 🦴Higher risk with: older age, increased comorbidity index, OP history, chronic use of opioids, low BMI 🦴Men and women were equally likely to fracture

Multiplex peripheral blood in 200+ ILD pts Differences in IL-17 RD-ILD>IPF> IPAF Higher IL-13 strongly asso w/ non-progression of ILD in RD-ILD, IPF & IPAF OR 0.4 Almost surprising considering known profibrotic role of IL-13 🧐 https://t.co/21UMq6w9hI Abs#1109 #ACR22 @Rheumnow https://t.co/7tfk74zH8A

• High Interleukin-13 Level Is Associated with Disease Stability in Interstitial …

#ACR22 Abstr#0826 2 years on since FDA approved #Tocilizumab in Adults Onset Still's Disease, real-world data from Japan affirmed its effectiveness and as a steroid-sparring agent @RheumNow https://t.co/jbmhEnGwXO

Stop repeating the #ANA test! 46% of all ANA tests were repeat tests in this study. #HealthCareCost #NoUtility #ChooseWisely abst#1278 @rheumnow #ACR22 https://t.co/K7oyqJYvi9

• ANA Testing Practices in the United States: A Population-Based Study Between 20…

Limited utility for using bone turnover markers in osteoporosis. Perhaps useful to assess adherence to oral therapy. @RheumNow #ACR22 #osteoporosis https://t.co/g6f7SnOzNR

Puechal et al RTX vs CYC induction in GPA: target trial emulation study. BVAS 0 and pred=<10mg at 6 months 73% RTX vs 40% CYC. RR 1.82[95%CI:1.22;2.73] @RheumNow #ACR22 Abstr#1084 https://t.co/6e8wutMC2H https://t.co/OpeajFVdJf

• Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with …